Life sciences · 2026
Pharmacological effects of nebivolol on endothelial response in a preeclampsia in vitro model.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bueno-Pereira Thaina Omia, de Andrade Alexandre Dorth, Zampieri Gabriela Morelli, Nunes Priscila Rezeck, Sandrim Valeria Cristina
Аннотация
UNLABELLED: Preeclampsia (PE) is a pregnancy-specific hypertensive disorder characterized by systemic endothelial dysfunction and a profound anti-angiogenic state driven by elevated soluble fms-like tyrosine kinase-1 (sFlt-1). While the third-generation β1-AR nebivolol promotes vasodilation partially via receptor β3-AR activation, whether its protective effects can reverse the complex anti-angiogenic and hypoxic stress of PE remains unclear.
AIMS: This study aimed to determine the functional and molecular effects of nebivolol in a PE-like endothelial microenvironment and to understand the specific contribution of β3-AR.
MATERIAL AND METHODS: Endothelial cells exposed to chemical hypoxia and 10% plasma from women with early-onset PE were treated with nebivolol, the selective β3-AR agonist CL316,243, or the β3-AR antagonist L-748,337. We quantified sFlt-1 secretion, evaluated the transcription of key angiogenic, vasoactive, and cytoprotective genes, and assessed cell migration using migration and transwell assays.
KEY FINDINGS: Nebivolol selectively modulated specific components of the PE phenotype, reducing sFlt-1 secretion, downregulating VEGFR2 and EDN1, and upregulating HMOX1. Conversely, it significantly inhibited endothelial cell migration. Crucially, selective β3-AR activation via CL316,243 failed to mirror these integrated responses, and β3-AR antagonism did not reverse nebivolol's actions.
SIGNIFICANCE: We conclude that nebivolol's protective effects in a PE-like environment do not depend primarily on β3-AR activation, but rather reflect a broader, pleiotropic vascular pharmacological profile. Translating these results clinically suggests that targeting single-receptor pathways may be insufficient in the complex environment of PE, positioning multi-target agents like nebivolol as candidates for modulating endothelial dysfunction in gestational hypertensive disorders.
AIMS: This study aimed to determine the functional and molecular effects of nebivolol in a PE-like endothelial microenvironment and to understand the specific contribution of β3-AR.
MATERIAL AND METHODS: Endothelial cells exposed to chemical hypoxia and 10% plasma from women with early-onset PE were treated with nebivolol, the selective β3-AR agonist CL316,243, or the β3-AR antagonist L-748,337. We quantified sFlt-1 secretion, evaluated the transcription of key angiogenic, vasoactive, and cytoprotective genes, and assessed cell migration using migration and transwell assays.
KEY FINDINGS: Nebivolol selectively modulated specific components of the PE phenotype, reducing sFlt-1 secretion, downregulating VEGFR2 and EDN1, and upregulating HMOX1. Conversely, it significantly inhibited endothelial cell migration. Crucially, selective β3-AR activation via CL316,243 failed to mirror these integrated responses, and β3-AR antagonism did not reverse nebivolol's actions.
SIGNIFICANCE: We conclude that nebivolol's protective effects in a PE-like environment do not depend primarily on β3-AR activation, but rather reflect a broader, pleiotropic vascular pharmacological profile. Translating these results clinically suggests that targeting single-receptor pathways may be insufficient in the complex environment of PE, positioning multi-target agents like nebivolol as candidates for modulating endothelial dysfunction in gestational hypertensive disorders.